• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Down Over 100 Points; Hibbett Reports Downbeat Sales

    3/15/24 9:58:18 AM ET
    $BTTX
    $CISS
    $HIBB
    $JTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Marine Transportation
    Consumer Discretionary
    Get the next $BTTX alert in real time by email

    U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 100 points on Friday.

    Following the market opening Friday, the Dow traded down 0.28% to 38,797.24 while the NASDAQ fell 0.67% to 16,020.07. The S&P 500 also fell, dropping, 0.58% to 5,120.59.

    Check This Out: Top 5 Industrials Stocks That May Fall Off A Cliff In Q1

     

    Leading and Lagging Sectors

     

    Energy shares jumped by 0.6% on Friday.

    In trading on Friday, information technology shares fell by 1.2%.

     

    Top Headline

     

    Hibbett Inc (NASDAQ:HIBB) reported downbeat fourth-quarter sales and issued weak guidance.

    Hibbett reported fourth-quarter FY24 sales growth of 1.8% year-on-year to $466.59 million, missing the analyst consensus estimate of $477.49 million. EPS of $2.55 missed the consensus estimate of $2.56.

    Hibbett expects FY25 sales to be flat to up 2%, with EPS of $8.00 – $8.75 versus the consensus of $8.82.

     

    Equities Trading UP

     

    Verb Technology Company, Inc. (NASDAQ:VERB) shares shot up 156% to $0.3580. VERB's MARKET.live launched Facebook and Instagram social shopping technology integration.

    Shares of Better Therapeutics, Inc. (NASDAQ:BTTX) got a boost, surging 118% to $0.0762. Better Therapeutics recently said it will seek strategic alternatives and will be delisted from the Nasdaq.

    Jet.AI Inc. (NASDAQ:JTAI) shares were also up, gaining 82% to $1.2300.

     

    Equities Trading DOWN

     

    C3is Inc. (NASDAQ:CISS) shares dropped 66% to $0.0270 after the company announced pricing of a $6 million underwritten public offering.

    Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) were down 32% to $1.05. SELLAS Life Sciences Group announced a $20 million registered direct offering and concurrent private placement of 13,029316 shares each for combined purchase price of $1.535/share.

    Lucy Scientific Discovery Inc. (NASDAQ:LSDI) was down, falling 32% to $1.14.

    Also Check This Out: Wall Street's Most Accurate Analysts Say Hold These 3 Tech Stocks Delivering High-Dividend Yields

     

    Commodities

     

    In commodity news, oil traded down 0.7% to $80.67 while gold traded down 0.3% at $2,161.80.

    Silver traded up 1.2% to $25.35 on Friday, while copper rose 1.3% to $4.0975.

     

    Euro zone

     

    European shares were higher today. The eurozone’s STOXX 600 rose 0.1%, London’s FTSE 100 rose 0.1% while Spain’s IBEX 35 Index rose 1.2% The German DAX gained 0.3% French CAC 40 rose 0.5% while Italy’s FTSE MIB Index gained 0.6%.

    The annual inflation rate in Italy was confirmed at 0.8% in February, while annual inflation rate in France fell to 3% in February from 3.1% a month ago.

     

    Asia Pacific Markets

     

    Asian markets closed mostly lower on Friday, with Japan’s Nikkei 225 falling 0.26%, Hong Kong’s Hang Seng Index falling 1.42%, China’s Shanghai Composite Index gaining 0.54% and India’s S&P BSE Sensex dipping 0.7%.

    China's new home prices fell by 1.4% year-over-year in February, while the People's Bank of China held the interest rate at 2.50%. The unemployment rate for Singapore was confirmed at 2.0% for the fourth quarter.

     

    Economics

     

    U.S. manufacturing production increased by 0.8% month-over-month in February.

    U.S. industrial production rose by 0.1% from the prior month in February.

    The NY Empire State Manufacturing Index fell to -20.9 in March versus -2.4 in February.

    Export prices in the U.S. increased 0.8% month-over-month in February, while import prices rose by 0.3%.

    Now Read This: How To Earn $500 A Month From Dollar General Stock Following Earnings Beat

    Get the next $BTTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTTX
    $CISS
    $HIBB
    $JTAI

    CompanyDatePrice TargetRatingAnalyst
    Hibbett Inc.
    $HIBB
    3/18/2024$82.00 → $74.00Outperform → Market Perform
    Telsey Advisory Group
    Hibbett Inc.
    $HIBB
    3/18/2024$72.00 → $82.00Buy
    Monness Crespi & Hardt
    Hibbett Inc.
    $HIBB
    3/13/2024$73.00 → $82.00Outperform
    Telsey Advisory Group
    Hibbett Inc.
    $HIBB
    11/22/2023$60.00 → $73.00Outperform
    Telsey Advisory Group
    Hibbett Inc.
    $HIBB
    11/22/2023$60.00 → $72.00Buy
    Monness Crespi & Hardt
    Hibbett Inc.
    $HIBB
    6/29/2023$37.00Neutral
    B. Riley Securities
    Hibbett Inc.
    $HIBB
    3/14/2023$69.00Hold
    Jefferies
    Hibbett Inc.
    $HIBB
    10/25/2022$75.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $BTTX
    $CISS
    $HIBB
    $JTAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Annual Letter to Shareholders: Data Center Developments

    LAS VEGAS, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Jet.AI Inc. ("Jet.AI or the "Company") (NASDAQ:JTAI), an emerging provider of high-performance GPU infrastructure and AI cloud services, today issued a letter to its shareholders highlighting key milestones and recent operational developments reached and its 2026 strategic priorities. Dear Shareholders, Over the past year, we put capital to work in three data center development projects, sponsored an AI infrastructure SPAC (NYSE:AIIA), and continued progressing toward the sale of our aviation business to flyExclusive (NYSE:FLYX). As of this writing, we have approximately $9 million of cash on the balance sheet and no debt. As we see it today,

    2/2/26 8:30:00 AM ET
    $AIIA
    $FLYX
    $JTAI
    Blank Checks
    Finance
    Transportation Services
    Consumer Discretionary

    C3is Inc. Provides Fleet Expansion Update in the Tanker Sector and Announces Management's Estimate of Net Asset Value

    ATHENS, Greece, Jan. 23, 2026 (GLOBE NEWSWIRE) -- C3is Inc. (NASDAQ:CISS) (the "Company"), a ship-owning company providing dry bulk and tanker seaborne transportation services, provided today an update on its fleet expansion, with the delivery of two MR product tankers expected between the first quarter and the third quarter of 2026, and announced management's estimate of the Company's Net Asset Value ("NAV") as of September 30, 2025. Fleet Expansion Update Following the delivery of the two MR product tankers scheduled to be delivered between the first quarter and the third quarter of 2026, and assuming no further vessel acquisitions or dispositions, the Company's fleet will consist of s

    1/23/26 8:30:00 AM ET
    $CISS
    Marine Transportation
    Consumer Discretionary

    C3is Inc. Announces the Acquisition of Two Medium Range Product Tankers

    ATHENS, Greece, Jan. 22, 2026 (GLOBE NEWSWIRE) -- C3is Inc. (NASDAQ:CISS) (the "Company"), a ship-owning company providing dry bulk and tanker seaborne transportation services, announced today the expansion of its fleet by entering into two Memoranda of Agreement for the acquisition of two MR product tankers with an approximate capacity of 50,000 dwt per vessel, both built in South Korea in 2008 and 2011, respectively (the "Transaction" or the "Acquisitions"). The purchase price is $16.88 million for the 2008-built tanker and $22.90 million for the 2011-built tanker. The vessels are expected to be delivered to the Company between the first and third quarters of 2026. Following completion

    1/22/26 4:10:00 PM ET
    $CISS
    Marine Transportation
    Consumer Discretionary

    $BTTX
    $CISS
    $HIBB
    $JTAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hibbett downgraded by Telsey Advisory Group with a new price target

    Telsey Advisory Group downgraded Hibbett from Outperform to Market Perform and set a new price target of $74.00 from $82.00 previously

    3/18/24 7:54:18 AM ET
    $HIBB
    Food Distributors
    Consumer Discretionary

    Monness Crespi & Hardt reiterated coverage on Hibbett with a new price target

    Monness Crespi & Hardt reiterated coverage of Hibbett with a rating of Buy and set a new price target of $82.00 from $72.00 previously

    3/18/24 7:46:04 AM ET
    $HIBB
    Food Distributors
    Consumer Discretionary

    Telsey Advisory Group reiterated coverage on Hibbett with a new price target

    Telsey Advisory Group reiterated coverage of Hibbett with a rating of Outperform and set a new price target of $82.00 from $73.00 previously

    3/13/24 7:58:34 AM ET
    $HIBB
    Food Distributors
    Consumer Discretionary

    $BTTX
    $CISS
    $HIBB
    $JTAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Varian John was granted 50,000 shares, increasing direct ownership by 218% to 72,900 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    1/9/26 4:43:43 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Van Nostrand Robert L was granted 50,000 shares, increasing direct ownership by 152% to 82,900 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    1/9/26 4:39:03 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Scheinberg David A was granted 50,000 shares, increasing direct ownership by 217% to 73,082 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    1/9/26 4:38:00 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTTX
    $CISS
    $HIBB
    $JTAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kalin Katherine Bach bought $100,806 worth of shares (63,400 units at $1.59), increasing direct ownership by 155% to 104,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    11/21/25 8:45:10 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Van Nostrand Robert L bought $14,800 worth of shares (10,000 units at $1.48), increasing direct ownership by 96% to 20,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    6/13/25 8:00:33 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wasman Jane bought $33,800 worth of shares (20,000 units at $1.69), increasing direct ownership by 192% to 30,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    6/2/25 4:42:07 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTTX
    $CISS
    $HIBB
    $JTAI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Jet.AI Inc.

    SCHEDULE 13D/A - Jet.AI Inc. (0001861622) (Subject)

    2/6/26 7:46:50 AM ET
    $JTAI
    Transportation Services
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13D/A filed by C3is Inc.

    SCHEDULE 13D/A - C3is Inc. (0001951067) (Subject)

    2/4/26 5:00:01 PM ET
    $CISS
    Marine Transportation
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Jet.AI Inc.

    SCHEDULE 13G/A - Jet.AI Inc. (0001861622) (Subject)

    2/4/26 4:05:23 PM ET
    $JTAI
    Transportation Services
    Consumer Discretionary

    $BTTX
    $CISS
    $HIBB
    $JTAI
    Financials

    Live finance-specific insights

    View All

    Annual Letter to Shareholders: Data Center Developments

    LAS VEGAS, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Jet.AI Inc. ("Jet.AI or the "Company") (NASDAQ:JTAI), an emerging provider of high-performance GPU infrastructure and AI cloud services, today issued a letter to its shareholders highlighting key milestones and recent operational developments reached and its 2026 strategic priorities. Dear Shareholders, Over the past year, we put capital to work in three data center development projects, sponsored an AI infrastructure SPAC (NYSE:AIIA), and continued progressing toward the sale of our aviation business to flyExclusive (NYSE:FLYX). As of this writing, we have approximately $9 million of cash on the balance sheet and no debt. As we see it today,

    2/2/26 8:30:00 AM ET
    $AIIA
    $FLYX
    $JTAI
    Blank Checks
    Finance
    Transportation Services
    Consumer Discretionary

    C3is Inc. Announces the Acquisition of Two Medium Range Product Tankers

    ATHENS, Greece, Jan. 22, 2026 (GLOBE NEWSWIRE) -- C3is Inc. (NASDAQ:CISS) (the "Company"), a ship-owning company providing dry bulk and tanker seaborne transportation services, announced today the expansion of its fleet by entering into two Memoranda of Agreement for the acquisition of two MR product tankers with an approximate capacity of 50,000 dwt per vessel, both built in South Korea in 2008 and 2011, respectively (the "Transaction" or the "Acquisitions"). The purchase price is $16.88 million for the 2008-built tanker and $22.90 million for the 2011-built tanker. The vessels are expected to be delivered to the Company between the first and third quarters of 2026. Following completion

    1/22/26 4:10:00 PM ET
    $CISS
    Marine Transportation
    Consumer Discretionary

    C3is Inc. reports third quarter and nine months 2025 financial and operating results

    ATHENS, Greece, Nov. 18, 2025 (GLOBE NEWSWIRE) -- C3is Inc. (NASDAQ:CISS) (the "Company"), a ship-owning company providing drybulk and tanker seaborne transportation services, announced today its unaudited financial and operating results for the third quarter and nine months ended September 30, 2025. OPERATIONAL AND FINANCIAL HIGHLIGHTS Our handysize dry bulk carriers are on time charters of short-term durations, producing steady cash flows, while our Aframax tanker operates in the spot market, currently achieving voyage charter rates of around $52,000 per day.All of our vessels are unencumbered.Fleet operational utilization of 67.7% for the three months ended September 30, 2025, mainly

    11/18/25 9:00:00 AM ET
    $CISS
    Marine Transportation
    Consumer Discretionary

    $BTTX
    $CISS
    $HIBB
    $JTAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Verb Technology Company Inc.

    SC 13G/A - Verb Technology Company, Inc. (0001566610) (Subject)

    11/15/24 8:24:57 PM ET
    $VERB
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by SELLAS Life Sciences Group Inc.

    SC 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)

    11/8/24 8:33:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verb Technology Company Inc.

    SC 13G/A - Verb Technology Company, Inc. (0001566610) (Subject)

    10/23/24 8:56:50 PM ET
    $VERB
    Other Consumer Services
    Consumer Discretionary

    $BTTX
    $CISS
    $HIBB
    $JTAI
    Leadership Updates

    Live Leadership Updates

    View All

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

    NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the addition of Linghua Wang, MD, PhD, to its Scientific Advisory Board (SAB). Dr. Wang is a widely respected leader in cancer research and translational science, and she joins the Company's SAB shortly after the appointments of Philip C. Amrein, MD, and Dr. Alex Kentsis, MD, PhD. "We are thrilled to welcome Dr. Wang to our Scientific Advisory Board," said Dragan Cicic, MD, Senior Vice President, Chief Development Officer

    7/7/25 8:45:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

    Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot

    6/24/25 12:52:00 PM ET
    $AUTL
    $CATX
    $INDP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations